Advances in the treatment of moderate-to-severe plaque psoriasis

Herrier, Richard N.
May 2011
American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p795
Academic Journal
Purpose. Advances in the treatment of moderate-to-severe plaque psoriasis, including new biological agents and related drugs, are reviewed. Summary. Most patients with psoriasis have mild disease that can be treated with topical agents alone; however, over one third of patients have more-extensive disease, called moderate-to-severe plaque psoriasis. Although effective, traditional therapies, including methotrexate, cyclosporine, acitretin, and phototherapy, have serious adverse effects that limit both the initiation and duration of treatment, necessitating sequential treatment regimens. With the increasing knowledge of the immune nature of the disease, biological agents that target T lymphocytes, tumor necrosis factor (TNF)-α, interleukin (IL)-12, and IL-23 have been used successfully in moderate-to-severe psoriasis. Etanercept, adalimumab, and infliximab are also highly effective in the treatment of moderate-tosevere plaque psoriasis. Ustekinumab, a new agent that targets IL-12 and IL-23, was approved for marketing in 2009 and offers similar efficacy and safety profiles to the anti-TNF agents. While the rapid onset and apparent lack of long-term toxicity of biological agents make them major advances in the treatment of more severe forms of psoriasis, the lack of extensive experience with these agents in patients with psoriasis leaves several unresolved issues that must be addressed before their exact place in therapy can be determined. Conclusion. With the development of biological therapies over the past 10 years, health care providers have a much broader choice of highly effective agents with which to treat patients suffering from moderate-to-severe plaque psoriasis. Though costly to use, biological agents offer considerable advantages over previously available systemic therapies.


Related Articles

  • Plaque psoriasis: A review of recent guidelines and pharmacologic therapies. Ballantini, Kacie; Flesner, Jennifer; Pitlick, Matthew // Formulary;Jan2011, Vol. 46 Issue 1, p18 

    Psoriasis is a common dermatologic condition manifested by plaque formation, which can be both difficult and expensive to treat. With several topical, oral, and biologic treatment options available, choosing a safe and effective regimen can be challenging. This article reviews treatment cost,...

  • Psoriasis vulgariste osteopontin ve iliÅŸkili sitokin düzeylerinin tedavi, hastalık aktivitesi ve komorbiditeler ile iliÅŸkisi. Bulu, Işıl; Gülekon, Ayla; Erdem, Özlem; Atak Yücel, Ayşegül; Çelik, Sevinç; Aral, Arzu // Archives of the Turkish Dermatology & Venerology / Turkderm;Sep2013, Vol. 47 Issue 3, p142 

    Background and Design: The IL23/Th17 axis is an exciting new pathway in the pathogenesis of psoriasis. Osteopontin (OPN) is a recently defined phosphorylated acidic glycoprotein which has an effect on psoriasis, especially over Th1/Th17 cells. We aimed to understand the role of OPN and Th1/Th17...

  • Current and Emerging Systemic Treatment Strategies for Psoriasis. Laws, Philip M.; Young, Helen S. // Drugs;2012, Vol. 72 Issue 14, p1867 

    Psoriasis is a common chronic inflammatory disease of the skin that has a significant impact on quality of life. A small number of systemic therapies are well established in psoriasis management. These have immunosuppressive and/ or anti-proliferative effects on the skin and immune system. As...

  • Türkiye Psoriasis Tedavi Kılavuzu-2012. Alper, Sibel; Akyol, Melih; Atakan, Nilgün; Başkan, Emel Bülbül; Gürer, Mehmet Ali; Koç, Erol; Onsun, Nahide; Özarmağan, Güzin; Şentürk, Nilgün; Yaylı, Savaş // Archives of the Turkish Dermatology & Venerology / Turkderm;2012, Vol. 46 Issue 4, p1 

    Psoriasis is a common, chronic, recurrent, inflammatory disease of the skin with unknown etiology. In addition to skin involvement, joint involvement is often seen in psoriasis; however as comorbidities including metabolic syndrome, cardiovascular diseases, psychological/psychiatric disorders...

  • Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Schipper, Lydia G.; Kievit, Wietske; den Broeder, Alfons A.; van der Laar, Mart A.; Adang, Eddy M. M.; Fransen, Jaap; van Riel, Piet L. C. M. // Rheumatology;Jul2011, Vol. 50 Issue 7, p1320 

    Objective. To perform a modelling study on the cost-effectiveness of three outcome-directed strategies in early RA patients: Strategy 1: starting MTX monotherapy, followed by the addition of LEF, followed by MTX with addition of anti-TNF; Strategy 2: start with MTX and LEF combination followed...

  • Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. Kyriakou, Aikaterini; Patsatsi, Aikaterini; Vyzantiadis, Timoleon-Achilleas; Sotiriadis, Dimitrios // Journal of Immunology Research;2014, p1 

    A case-control study was performed to assess the serum levels of TNF-α, IL-12/23p40, and IL-17 in patients with plaque psoriasis, compare them with healthy controls, and correlate them with disease severity, as represented by Psoriasis Area Severity Index (PASI). 32 consecutively selected,...

  • Most of the excess risk is related to the disease, not the treatment. Assassi, Shervin // BMJ: British Medical Journal;2/6/2016, Vol. 352 Issue 8043, pi472 

    The author comments on a study by P. Raaschou and colleagues about the risk of squamous cell cancer and basal cell cancer in patients with rheumatoid arthritis, undergoing biologics-naive and tumour necrosis factor inhibitor treatments.

  • Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNFα Agent. Bertoldi, Ilaria; Filippou, Georgios; Scirè, Carlo Alberto; Picerno, Valentina; di Sabatino, Valentina; Adinolfi, Antonella; Pierguidi, Serena; Galeazzi, Mauro; Frediani, Bruno // ISRN Rheumatology;2013, p1 

    Background. Bone damage in rheumatoid arthritis (RA) and in psoriatic arthritis (PsA) includes an accelerated bone mineral density (BMD) reduction. The objective was to evaluate BMD variations of the metacarpophalangeal joints (MCPs) in patients starting treatment with methotrexate (MTX) or...

  • Biological Treatment of Psoriasis. Gundogdu, Evren; Başpınar, Yücel; Karasulu, Hatice Yesim // Clinical Medicine Insights: Dermatology;2013, Issue 6, p19 

    Psoriasis is a common, chronic, inflammatory disease affecting millions of people around the world. Presented in the first 5 parts of the American Academy of Dermatology Psoriasis Guidelines of Care is evidence supporting the use of topical treatments, phototherapy, traditional systemic agents,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics